NATICK, Mass. and CHICAGO, March 29 /PRNewswire-FirstCall/ -- Boston
Scientific Corporation (NYSE: BSX) today announced results from an analysis
of 4,772 patients from its TAXUS ARRIVE 1 and 2 registries, designed to
assess the performance of the TAXUS(R) Express2(TM) Paclitaxel-Eluting
Coronary Stent System in real-world practice. The one-year pooled ARRIVE
data confirmed the known higher mortality rate for diabetics versus
non-diabetics with cardiovascular disease(1), but showed that the TAXUS
Stent had similarly low rates of stent-related cardiac death, myocardial
infarction (MI), stent thrombosis, and major cardiac events (MCE) across
those two patient subsets. The study also showed similar rates of target
vessel re-intervention (TVR) and TAXUS-related TVR in indicated patients(2)
per the European Union (EU) label, whether or not they had diabetes.
Analysis of the data was presented by D. Lynn Morris, M.D., at the SCAI
Annual Scientific Sessions in Partnership with the ACC/i2 Summit in
Chicago.

The pooled analysis included one-year data on 1,530
medication-requiring diabetic patients and 3,242 non-diabetic patients from
the ARRIVE registry program. Due to significant disparity in baseline
characteristics between diabetic and non-diabetic patients, propensity
score analysis was used to allow for adjustment of baseline differences
(other than the presence of diabetes) between the two groups.

The results showed diabetic patients had the well-known higher overall
adjusted one-year mortality rate than patients without diabetes (3.7% vs.
2.3%, respectively, p=0.016), with the difference being driven by the
cardiac death rate (2.3% vs. 1.2%, p=0.014), and reflecting the more
advanced cardiac disease associated with diabetes. However, this difference
was not related to the TAXUS Stent as the TAXUS Stent-related cardiac death
rates at one-year were comparable in diabetics and non-diabetics,
respectively (1.0% vs. 0.7%, p=0.29) in this patient population(2).
Additionally, TAXUS Stent-related MCE rates (cardiac death, MI, and
re-intervention) at one year were comparable (5.7% vs. 5.6%, p=0.80), as
was the incidence of TAXUS Stent-related MI (1.6% vs. 1.2%, p=0.26), in
both groups. Stent thrombosis at one year was low and showed no significant
difference between diabetics and non-diabetics under Protocol definition
(1.5% vs. 1.3%, p=0.59) or ARC Definite/Probable (1.7% vs. 1.2%, p=0.29).
Unadjusted one-year rates of TAXUS Stent-related cardiac death, TAXUS
Stent-related MCE, TAXUS Stent-related MI, and protocol-defined stent
thrombosis showed no differences between the two populations (p-values of
0.30, 0.74, 0.31, and 0.65, respectively), suggesting that the safety
profile is comparable for the two groups despite increased underlying risk
in patients with diabetes.

Additionally, the ARRIVE analysis confirmed that the TAXUS Stent
maintained comparable re-intervention rates in the diabetic and
non-diabetic patient populations in ARRIVE 1 and 2. Rates of one-year TVR,
whether adjusted or unadjusted, were similar between the patient groups
(6.1% vs. 6.0%, p=0.80, adjusted). TAXUS Stent-related re-intervention of a
target vessel (equivalent to target lesion revascularization, or TLR) was
also similar between the patient groups (4.3% vs. 4.5%, p=0.70), despite
the known higher risk for re-intervention in diabetic patients.

"The ARRIVE diabetic subset data demonstrated that the TAXUS Stent
mitigated the adverse effect of diabetes as a risk factor for restenosis
and repeat procedures in the patients studied," said Dr. Morris of the
Albert Einstein Medical Center in Philadelphia, PA. "While the diabetic
patients had more cardiac risk factors and co-morbidities than
non-diabetics, the TAXUS- related cardiac death, MI and stent thrombosis in
the ARRIVE 1 and 2 registries were similar in both groups, even without
adjustment for risk factors."

"Our extensive ARRIVE registries provide valuable insights into
diabetic patients who are often at higher risk for mortality and repeat
stenting procedures," said Paul LaViolette, Chief Operating Officer at
Boston Scientific. "The ARRIVE data demonstrated that the TAXUS Stent
neutralized diabetes as a risk factor for clinical restenosis in the
patients studied."

The growing diabetic subset accounts for more than one-quarter of all
coronary interventional procedures in the United States. Diabetes is
generally associated with an increased risk of cardiovascular events and
patients with diabetes are more likely than non-diabetic patients to
require repeat procedures due to a higher incidence of restenosis following
angioplasty and stenting.

The safety and effectiveness of the TAXUS Express Stent has not been
established in patients with diabetes in the United States.

Boston Scientific is a worldwide developer, manufacturer and marketer
of medical devices whose products are used in a broad range of
interventional medical specialties. For more information, please visit:
http://www.bostonscientific.com.

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements within the
meaning of Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements may be identified by words like "anticipate,"
"expect," "project," "believe," "plan," "estimate," "intend" and similar
words. These forward- looking statements are based on our beliefs,
assumptions and estimates using information available to us at the time and
are not intended to be guarantees of future events or performance. These
forward-looking statements include, among other things, statements
regarding clinical trials, regulatory approvals, competitive offerings,
product performance and our market position. If our underlying assumptions
turn out to be incorrect, or if certain risks or uncertainties materialize,
actual results could vary materially from the expectations and projections
expressed or implied by our forward-looking statements. These factors, in
some cases, have affected and in the future (together with other factors)
could affect our ability to implement our business strategy and may cause
actual results to differ materially from those contemplated by the
statements expressed in this press release. As a result, readers are
cautioned not to place undue reliance on any of our forward- looking
statements.

Factors that may cause such differences include, among other things:
future economic, competitive, reimbursement and regulatory conditions; new
product introductions; demographic trends; intellectual property;
litigation; financial market conditions; and, future business decisions
made by us and our competitors. All of these factors are difficult or
impossible to predict accurately and many of them are beyond our control.
For a further list and description of these and other important risks and
uncertainties that may affect our future operations, see Part I, Item 1A-
Risk Factors in our most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, which we may update in Part II, Item 1A
- Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file
thereafter. We disclaim any intention or obligation to publicly update or
revise any forward- looking statements to reflect any change in our
expectations or in events, conditions, or circumstances on which those
expectations may be based, or that may affect the likelihood that actual
results will differ from those contained in the forward-looking statements.
This cautionary statement is applicable to all forward-looking statements
contained in this document.

CONTACT: Paul Donovan

508-650-8541 (office)

508-667-5165 (mobile)

Media Relations

Boston Scientific Corporation

Larry Neumann

508-650-8696 (office)

Investor Relations

Boston Scientific Corporation

(1) Rosamond W, Flegal K, Furie K, et al., ''Heart disease and stroke

statistics--2008 update: a report from the American Heart Association

Statistics Committee and Stroke Statistics Subcommittee.''

Circulation. 2008; 117(4):e25-146.

(2) Excludes the following patient and lesion characteristics that are

(Date:12/9/2016)... ... 09, 2016 , ... The Justin Veatch Fund announced Thursday that ... the film Whispering Spirits and its discussion guide for use by all ... tool in the war against teen drug abuse. NCADD is the oldest anti-addiction ...

(Date:12/9/2016)... ... 09, 2016 , ... MEDI+SIGN®, a provider of fully-automated patient ... solution for Emergency Departments (ED) has been added to their portfolio. Housed in ... rooms, and with a simplified pallet of information available to the patient, the ...

(Date:12/8/2016)... ... ... CURE Media Group, the nation’s leading digital and print media enterprise focused on ... efforts to combat lung cancer, announced CURE Media Group President Michael J. Hennessy, Jr. ... honored to team up with Upstage Lung Cancer in order to make major strides ...